

Rebecca J. Dennis,<sup>a‡</sup> Elena Micossi,<sup>a</sup> Joanne McCarthy,<sup>a</sup> Elin Moe,<sup>b</sup> Elspeth J. Gordon,<sup>a</sup> Sigrid Kozielski-Stuhrmann,<sup>a</sup> Gordon A. Leonard<sup>a</sup> and Sean McSweeney<sup>a\*</sup>


<sup>a</sup>Macromolecular Crystallography Group, European Synchrotron Radiation Facility, 38043 Grenoble CEDEX 9, France, and <sup>b</sup>The Norwegian Structural Biology Centre, University of Tromsø, N-9037 Tromsø, Norway

<sup>‡</sup> Current address: York Structural Biology Laboratory, Chemistry Department, University of York, England.

Correspondence e-mail: mcsweeney@esrf.fr

Received 10 February 2006  
Accepted 7 March 2006

**PDB References:** manganese superoxide dismutase, crystal form I, 2ce4, r2ce4sf; crystal form II, 2cdy, 2cdysf.



© 2006 International Union of Crystallography  
All rights reserved

## Structure of the manganese superoxide dismutase from *Deinococcus radiodurans* in two crystal forms

The structure of the manganese superoxide dismutase (Mn-SOD; DR1279) from *Deinococcus radiodurans* has been determined in two different crystal forms. Both crystal forms are monoclinic with space group  $P2_1$ . Form I has unit-cell parameters  $a = 44.28$ ,  $b = 83.21$ ,  $c = 59.52$  Å,  $\beta = 110.18^\circ$  and contains a homodimer in the asymmetric unit, with structure refinement ( $R = 16.8\%$ ,  $R_{\text{free}} = 23.6\%$ ) carried out using data to  $d_{\text{min}} = 2.2$  Å. Form II has unit-cell parameters  $a = 43.57$ ,  $b = 87.10$ ,  $c = 116.42$  Å,  $\beta = 92.1^\circ$  and an asymmetric unit containing two Mn-SOD homodimers; structure refinement was effected to a resolution of 2.0 Å ( $R = 17.2\%$ ,  $R_{\text{free}} = 22.3\%$ ). The resulting structures are compared with that of Mn-SOD from *Escherichia coli*, with which they are shown to be essentially isostructural.

### 1. Introduction

*Deinococcus radiodurans* (DEIRA) is an aerobic, non-pathogenic, red-pigmented Gram-positive bacterium that exhibits significant resistance to ionizing and ultraviolet radiation, desiccation and the presence of reactive oxygen species (ROS; Minton, 1994; Mattimore & Battista, 1996; Battista, 1997). The capability of DEIRA to withstand acute radiation doses of up to 1500 krad is intriguing and the bacterium has been the subject of intensive investigation in order to try to understand how this is possible. Exposure to such high doses of ionizing radiation causes massive damage to genomic DNA and a phenomenal capability of DEIRA to repair such damage, perhaps aided by a unique packaging of DNA in its cells, is thought to be responsible for the bacterium's ability to recover its viability (Minton, 1994; Makarova *et al.*, 2001; Levin-Zaidman *et al.*, 2003). However, it should be noted that the damaging effects of ionizing radiation are enhanced in the presence of oxygen, as ROS such as the hydroxyl radical (OH $\cdot$ ), the superoxide radical (O $_2^-$ ), hydrogen peroxide (H $_2$ O $_2$ ) and organic hydroperoxides which can also cause damage to cellular material are produced (Misra & Fridovich, 1976). Limiting the damage caused to DNA by ROS must therefore also be important to the ability of DEIRA to withstand the toxic effects of ionizing radiation.

As part of a structural genomics project focusing on the determination of the three-dimensional structures of gene products that may be important in contributing to the extremophile nature of DEIRA strain R1, we have targeted a number of enzymes involved in the neutralization of ROS. One such enzyme is the manganese-dependent superoxide dismutase (Mn-SOD; DR1279; EC 1.15.11), which catalyses the disproportionation of superoxide radicals to oxygen and hydrogen peroxide (Fridovitch, 1986).

At first sight, Mn-SOD from DEIRA might seem to be a strange choice of target. After all, the three-dimensional structures and reaction mechanisms of Mn-SODs from other organisms (including that from *Escherichia coli*) have been extensively studied and characterized (Borgstahl *et al.*, 2000; Edwards *et al.*, 2001 and references therein). The amino-acid sequence of DEIRA Mn-SOD has (apart from a six-residue insert between residues 91 and 92) 57% identity (Fig. 1) with its homologue from *E. coli* and therefore its three-dimensional structure and mechanism of action must be very similar to those of *E. coli* Mn-SOD. However, Mn-SOD is highly (Chou & Tan, 1990) and apparently constitutively (Lipton *et al.*, 2002)

expressed by DEIRA and DEIRA mutants lacking Mn-SOD are much more sensitive to the effects of ionizing radiation than are both wild-type DEIRA or DEIRA mutants that do not express the catalase KatA (Markillie *et al.*, 1999). This suggests that the neutralization of superoxide radicals is more important to the extremophile nature of DEIRA than the neutralization of hydrogen peroxide. Investigations of the structure of DEIRA Mn-SOD may provide structural reasons for the importance of Mn-SOD to the survival of DEIRA. We therefore now report the three-dimensional structure of Mn-SOD from DEIRA (Mn-SOD<sub>Dr</sub>) in two different crystal forms as determined using single-crystal X-ray diffraction techniques and, in particular, compare them with the crystal structure of the Mn-SOD from *E. coli* (Mn-SOD<sub>Ec</sub>; PDB code 1vew; Edwards *et al.*, 1998).

2. Materials and methods

2.1. Protein cloning, expression and purification

The Mn-SOD gene from *D. radiodurans* (DR1279) was amplified by *Pfu* DNA polymerase, subcloned into a Gateway pDest17 vector (Invitrogen) containing a 2.6 kDa N-terminal fusion tag that includes a hexahistidine region and transformed into BL21(DE3)pLysS *E. coli* cells (Novagen). One colony of bacteria was used to inoculate 10 ml of Luria-Bertani (LB) broth to which ampicillin (50 µg ml<sup>-1</sup>) and chloramphenicol (34 µg ml<sup>-1</sup>) had been added. An overnight culture was then grown at 310 K, shaking the flasks at ~200 rev min<sup>-1</sup>. This was then centrifuged at 1500g for 10 min with the resulting pellet being resuspended in 10 ml 2×YT medium and used to inoculate 500 ml 2×YT medium supplemented with ampicillin (100 µg ml<sup>-1</sup>) and chloramphenicol (34 µg ml<sup>-1</sup>). This was incubated at 295 K until the cell density reached an OD<sub>600</sub> of ~0.6. The production of Mn-SOD<sub>Dr</sub> was induced with 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) and cell growth continued for ~16 h at 295 K. The cells were then harvested by centrifugation at 4500g for 20 min at 277 K. The pellet was resuspended in 10 ml of an ice-cold lysis buffer consisting of 100 mM Tris-HCl pH 7.5, 150 mM NaCl and 10 mM imidazole supplemented with 1 mM MgCl<sub>2</sub>, 10 µg ml<sup>-1</sup> DNaseI, 100 µg ml<sup>-1</sup> lysozyme and a Complete Mini EDTA-free cocktail of antiproteases (Roche). The cells were then sonicated on ice using five 30 s pulses and the cell debris was removed by centrifugation at 17 000g for 90 min at 277 K.

The resulting supernatant was applied onto a Hi-Trap column (Amersham Biosciences) previously loaded with 0.1 M nickel sulfate and pre-equilibrated with a buffer consisting of 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 2 mM imidazole and 2 mM MnCl<sub>2</sub> (buffer A). Mn-SOD<sub>Dr</sub> was eluted using a 50 ml linear gradient from buffer A to a buffer consisting of 20 mM Tris-HCl pH 7.5, 500 mM NaCl, 500 mM imidazole and 2 mM MnCl<sub>2</sub> using a flow rate of 1 ml min<sup>-1</sup>.

Mn-SOD<sub>Dr</sub> eluted at an imidazole concentration of ~250 mM. The fractions containing Mn-SOD<sub>Dr</sub> were then pooled and dialysed against a buffer comprising 10 mM Tris-HCl pH 7.5 and 1 mM EGTA (buffer B) and applied onto a 1 ml Mono-Q ion-exchange chromatography column (Amersham Biosciences) previously equilibrated with buffer B. Mn-SOD<sub>Dr</sub> was eluted using a 30 ml linear gradient from buffer B to a buffer consisting of 20 mM Tris-HCl pH 7.5, 1 mM EGTA and 1 M NaCl. SDS-PAGE analysis (data not shown) confirmed that pure, tagged, recombinant Mn-SOD<sub>Dr</sub> of the correct molecular weight (231 amino acids, ~26 kDa) had been obtained with high degree of purity using the above protocol. For crystallization trials, protein stock solutions were prepared by pooling fractions containing the pure protein, dialysing them against a buffer consisting of 10 mM Tris-HCl pH 7.5, 20 mM NaCl and 1 mM MnCl<sub>2</sub> and then concentrating to 10 mg ml<sup>-1</sup>. The stock solution used in the activity measurements described in §2.2 was prepared as described above except that the protein concentration was 20 mg ml<sup>-1</sup>.

2.2. Measurement of DEIRA Mn-SOD activity

The specific activity of Mn-SOD<sub>Dr</sub> was determined using an SOD Assay Kit-WST (Dojindo Molecular Technologies Inc., Maryland, USA) according to the manufacturer's protocol (Dojindo Molecular Technologies Inc., 2005). WST-1 [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] is a soluble tetrazolium salt that produces a water-soluble formazan dye upon reduction with a superoxide anion. The rate of the reduction with O<sub>2</sub><sup>-</sup> is linearly related to xanthine oxidase activity and is inhibited by SOD. Thus, the IC<sub>50</sub> (50% inhibition activity of SOD or SOD-like materials) can be determined by a colorimetric method. Standard solutions of Mn-SOD<sub>Ec</sub> (Sigma-Aldrich Inc., MO, USA) were prepared at concentrations of 200, 100, 50, 20, 10, 5, 1, 0.1, 0.05, 0.01 and 0.001 U ml<sup>-1</sup> in the SOD Assay Kit-WST dilution buffer and Mn-SOD<sub>Dr</sub> (20 mg ml<sup>-1</sup>) obtained as described above was diluted 100, 500 and 1000 times in the same buffer. 20 µl each of the solutions of Mn-SOD<sub>Ec</sub>, Mn-SOD<sub>Dr</sub> and three blank solutions (water blank 1, sample blank 2 and water blank 3) were transferred in triplets into microplate wells and 200 µl WST working solution and 20 µl enzyme working solution supplied by the manufacturer was added (except for blank 2 and 3, to which 20 µl dilution buffer was added). The reactions were incubated at 310 K for 20 min and absorbance was read at 405 nm in a V<sub>max</sub> microplate reader (Molecular Devices Corp., CA, USA). The SOD activity (inhibition rate) was calculated using the equation

$$\frac{(A_{\text{blank 1}} - A_{\text{blank 3}}) - (A_{\text{sample}} - A_{\text{blank 2}})}{(A_{\text{blank 1}} - A_{\text{blank 3}})} \times 100$$




Figure 1 CLUSTAL W (Thompson *et al.*, 1994) amino-acid sequence alignment of Mn-SOD<sub>Ec</sub> (top) and Mn-SOD<sub>Dr</sub>. Superimposed on these is a secondary-structure assignment as defined in Edwards *et al.* (1998). This figure was produced using *ESPrIpt* (Gouet *et al.*, 2003).

**Table 1**

Summary of crystal parameters, data-collection and refinement statistics from crystal forms I and II of Mn-SOD<sub>Dr</sub>.

Values in parentheses are for the highest resolution shell.

	Crystal form I	Crystal form II
Data collection and processing		
Unit-cell parameters (Å, °)	$a = 44.28, b = 83.21,$ $c = 59.52, \beta = 110.18$	$a = 43.57, b = 87.10,$ $c = 116.42, \beta = 92.1$
Space group	$P2_1$	$P2_1$
Wavelength (Å)	0.933	0.933
Resolution range (Å)	29.4–2.2 (2.32–2.2)	41.2–2.0 (2.11–2.0)
No. of observations	69134 (9955)	452450 (26160)
No. of unique reflections	20567 (2982)	48281 (3564)
Completeness† (%)	99.8 (99.8)	82.2 (41.7)
$R_{\text{sym}}$ (%)	5.7 (16.5)	7.5 (14.5)
$\langle I/\sigma(I) \rangle$	15.6 (6.0)	31.8 (9.0)
Multiplicity	3.4 (3.3)	9.4 (7.3)
Final model composition		
Amino-acid residues‡	A1–A43, A45–A89, A96–A210, B1–B90, B96–B210	A1–A92, A99–A210, B1–B43, B46–B91, B97–B210, C1–C91, C94–C210, D1–D91, D96–D210
Protein atoms	3248	6481
Mn <sup>3+</sup> ions	2	4
Water molecules	366	567
Refinement details		
$R/R_{\text{free}}$ (%)	16.8 (20.9)/23.6 (26.6)	17.4 (18.4)/22.3 (23.1)
No. of reflections	19552/996	45781/2483
$\langle B \rangle$ (Å <sup>2</sup> )	25.3	22.1
E.s.u. (based on $R_{\text{free}}$ ) (Å)	0.23	0.19
R.m.s. deviations from ideal geometry		
Bond lengths (Å)	0.012	0.012
Bond angles (°)	1.30	1.23
Ramachandran plot		
Favoured regions (%)	94.8/93.9	96.1/92.6/93.9/94.0
Allowed regions (%)	3.4/5.0	2.8/6.3/3.9/4.0
Generously allowed regions (%)	1.7/1.1	1.1/1.1/1.7/1.1
Disallowed regions (%)	0.0/0.0	0.0/0.0/0.6 (Cys96)/0.0

† For crystal form II the completeness in the resolution range 41.2–2.25 Å is 95.4%. ‡ Some side chains are disordered and are not included in the final model. For crystal form I residues A126, B66 and B120 are truncated at C<sup>δ</sup>, residues A40, A104, B40 and B43 are truncated at C<sup>γ</sup> and residues A142 and B142 are truncated at C<sup>β</sup>. For crystal form II residues A142, A210, A53, A102, B40, B46, B53, B105, C91, C210, D139 and D158 are truncated at C<sup>β</sup>, while residues B23 and C94 are truncated at S<sup>δ</sup> and C<sup>γ</sup>, respectively.

and plotted onto an inhibition curve. The amount of Mn-SOD<sub>Dr</sub> in the samples was determined from the curve in U ml<sup>-1</sup> and used for calculations of the specific activity.

### 2.3. Crystallization, data collection and processing, structure solution and refinement

Crystals of Mn-SOD<sub>Dr</sub> appeared from several hanging-drop trials in which 2 µl protein stock solution and 2 µl reservoir solution were equilibrated at 293 K against 1 ml reservoir solution. Those most amenable to the collection of good-quality X-ray diffraction data were obtained using reservoir solutions consisting of either 10 mM Tris–HCl pH 8.5, 20 mM MnCl<sub>2</sub>, 30% PEG 4000 (crystal form I) or 10 mM Tris–HCl pH 8.5, 10% PEG 8000, 14% PEG 1500 and 10 mM MnCl<sub>2</sub> (crystal form II). In both cases further cryoprotection of the crystals was not required and both were flash-frozen in a stream of gaseous nitrogen prior to data collection.

X-ray diffraction data from a single crystal of form I (Table 1) were collected at 100 K and  $\lambda = 0.933$  Å on beamline ID14-EH1 of the ESRF, with the intensity data being indexed and integrated using the program *MOSFLM*, scaled and merged using *SCALA* and structure factors obtained using the program *TRUNCATE*. The indexing, integration, scaling and merging procedures clearly showed the crystals to be monoclinic, with unit-cell parameters  $a = 44.28, b = 83.21,$

$c = 59.52$  Å,  $\beta = 110.18^\circ$ ; examination of systematic absences in the intensity data indicated the space group to be  $P2_1$ . A calculated Matthews coefficient of  $2.2 \text{ \AA}^3 \text{ Da}^{-1}$  and a theoretical solvent content of  $\sim 43\%$  are consistent with the asymmetric unit containing two Mn-SOD monomers.

X-ray diffraction data from a single crystal of form II (Table 1) were also collected at 100 K on beamline ID14-EH1, with the intensity data being treated in the same way as for form I. The crystals of form II are also monoclinic, with space group  $P2_1$  and unit-cell parameters  $a = 43.57, b = 87.10, c = 116.42$  Å,  $\beta = 92.1^\circ$ . For this crystal form a calculated Matthews coefficient of  $2.3 \text{ \AA}^3 \text{ Da}^{-1}$  and a theoretical solvent content of  $\sim 47\%$  are consistent with the asymmetric unit containing four Mn-SOD monomers.

Structure solution for crystal form I was carried out using the molecular-replacement (MR) technique as implemented in the program *CNS* (Brünger *et al.*, 1998). The search model was a monomer from the crystal structure of Mn-SOD<sub>Ec</sub> (PDB code 1wew; Edwards *et al.*, 1998) stripped of all solvent molecules and metal ions which was modified such that the residues in two loop regions (44–46, 92–95; Mn-SOD<sub>Ec</sub> numbering) were removed and amino-acid residues larger in the sequence of Mn-SOD<sub>Dr</sub> than in that of Mn-SOD<sub>Ec</sub> (see Fig. 1 for the sequence alignment) were truncated to alanine. The MR protocol used data in the resolution range 20.0–4.0 Å, resulted in Patterson and packing correlation coefficients of 58.0 and 61.0%, respectively, and confirmed that form I contains two molecules arranged as a homodimer in the asymmetric unit. The MR solution was then subjected to a round of rigid-body refinement using data in the range 40.0–3.5 Å, yielding  $R = 34.3\%$ ,  $R_{\text{free}} = 34.6\%$ . An initial round of simulated-annealing-based model refinement was then carried out using *CNS*. This was followed by a refinement protocol using the program *REFMAC5* (Winn *et al.*, 2001 and references therein) interspersed with rounds of manual rebuilding using the program *QUANTA* (Accelrys Inc.; <http://www.accelrys.com>), during which the model of Mn-SOD<sub>Dr</sub> was improved and water molecules and Mn<sup>3+</sup> ions included.

Structure solution for crystal form II was also carried out using the MR technique, this time using the program *AMoRe* (Navaza, 1994). The search model was a monomer from the partially refined crystal form I structure of Mn-SOD<sub>Dr</sub>, stripped of all solvent molecules and Mn<sup>3+</sup> ions. The MR protocol was carried out using data in the resolution range 15–3 Å, resulted in  $R = 35.2\%$ ,  $CC_{(\text{Fobs}, \text{Fcalc})} = 66.8\%$  and clearly showed that form II contains four molecules arranged in two homodimers in the asymmetric unit. Model refinement was carried out using the program *REFMAC5* interspersed with rounds of manual rebuilding using the program *O* (Jones *et al.*, 1991), during which the model was improved and water molecules and Mn<sup>3+</sup> ions were included. Details concerning diffraction data quality and showing the results of both refinement protocols are shown in Table 1. The programs *MOSFLM*, *SCALA*, *TRUNCATE*, *REFMAC5* and *AMoRe* are from the *CCP4* package (Collaborative Computational Project, Number 4, 1994).

### 3. Results and discussion

The composition of the final refined models for both crystal forms of Mn-SOD<sub>Dr</sub> are summarized in Table 1. Briefly, crystal form I contains a homodimer in the asymmetric unit and the model consists of amino-acid residues A1–A43, A45–A89, A96–A210, B1–B90, B96–B210, two Mn<sup>3+</sup> ions and 366 solvent molecules. Crystal form II contains two homodimers in the asymmetric unit, with the final refined model consisting of residues A1–A92, A99–A210, B1–B43, B46–B91, B97–




B210, C1–C91, C94–C210, D1–D91, D96–D210, four Mn<sup>3+</sup> ions and 567 solvent molecules. For both crystal forms the residue-numbering scheme refers to the sequence of DR1279 as deposited in the UniProtKB/Swiss-Prot database (<http://www.expasy.org>; primary accession No. Q9RUV2) and the final models described ignore residues from the purification tag modelled into electron density.

The three-dimensional structures of all the monomers found in both crystal forms are extremely similar, yielding r.m.s. deviations in C<sup>α</sup> positions of 0.26, 0.30, 0.30, 0.31 and 0.32 Å when monomer A of crystal form I is superimposed on monomer B of crystal form I and monomers A, B, C and D of crystal form II, respectively.

During the course of this work, coordinates for an independently determined structure of DR1279 in crystal form II described above were deposited in the Protein Data Bank (PDB code 1y67; S. Chan, S. Tanaka, M. R. Sawaya & L. J. Perry, unpublished work). Superposing the structure of monomer A in crystals forms I and II as determined in this work with the four SOD monomers found the asymmetric unit of form II as determined by Chan and coworkers results in r.m.s. deviations in C<sup>α</sup> positions of 0.26, 0.28, 0.38 and 0.32 Å (crystal form I) and 0.35, 0.25, 0.26 and 0.32 Å (crystal form II), respectively. Similarly, superimposing the AB homodimer in crystal forms I and II with the AB homodimer found in the structure deposited in the PDB results in r.m.s. deviations in C<sup>α</sup> positions of 0.30 and 0.48 Å, respectively. Thus, the structures determined in this work and that determined by Chan and coworkers are essentially identical. However, it is intriguing to note that in the structure of DR1279 as determined by Chan and coworkers the metal ions bound to the protein are assigned as Fe<sup>3+</sup> rather than Mn<sup>3+</sup>. This is despite the fact that DR1279 is clearly annotated as an Mn-SOD in the UniProtKB/Swiss-Prot database (see <http://ca.expasy.org/uniprot/Q9RUV2>) and that in the sequence of DR1279 the residues proposed as being the most likely candidates as markers for distinguishing between Mn-SODs and Fe-SODs (Parker & Blake, 1988) clearly indicate DR1279 to be a Mn-SOD. Moreover, the wavelength (1.1 Å) at which Chan and coworkers collected diffraction data for their structure solution does not allow one to distinguish between Fe<sup>3+</sup> and Mn<sup>3+</sup>.

Nevertheless, in all cases the three-dimensional structures of the Mn-SOD<sub>D<sub>r</sub></sub> monomers (Fig. 2a) are very similar to those reported in crystal structures of Mn-SOD<sub>E<sub>c</sub></sub> (Edwards *et al.*, 1998, 2001; Borgstahl *et al.*, 2000). Similarly, the structures of the physiologically relevant Mn-SOD<sub>D<sub>r</sub></sub> dimers (Fig. 2b) in the crystal structures reported here and by Chan and coworkers are essentially isostructural to those found for Mn-SOD<sub>E<sub>c</sub></sub> and other Mn-SODs. The r.m.s. deviations between around 400 common C<sup>α</sup> positions from superpositions of the Mn-SOD<sub>E<sub>c</sub></sub> dimer and those found in crystal forms I and II of Mn-SOD<sub>D<sub>r</sub></sub> average around 0.75 Å.

The metal-ion coordination sphere, which is absolutely conserved in all Mn-SODs, consists of the side chains of the amino-acid residues His26, His80, Asp172 and His176, which along with a conserved water molecule are arranged in a trigonal bipyramidal geometry around the metal ion. As in the structures of other Mn-SODs, the active site lies at the bottom of a funnel with



**Figure 2**  
 (a) Stereoview of a ribbon representation of the structure of a physiologically relevant Mn-SOD<sub>D<sub>r</sub></sub> dimer. The two monomers making up the dimer are coloured lime-green (with C<sup>α</sup> also shown) and cyan, respectively, with the positions of the Mg<sup>3+</sup> ions shown in magenta. The C-terminus of each monomer is coloured red and the N-terminus is blue. Residues forming part of the six-residue QGQNGA insert are numbered to show the likely position of disordered residues with respect to the rest of the protein. (b) A superposition of the CD dimer found in crystal form II of Mn-SOD<sub>D<sub>r</sub></sub>, and the dimer found in the crystal structure of Mn-SOD<sub>E<sub>c</sub></sub>. This shows that both monomers and dimers of the two Mn-SODs are essentially isostructural. The figure was produced using PyMOL (DeLano, 2002).

access to the catalytic centre being guarded by several so-called 'gateway residues' (see Fig. 1; Edwards *et al.*, 2001). These residues are very highly conserved throughout Mn-SOD sequences. In Mn-SOD<sub>Dr</sub> these residues are His30, Tyr34, Gln151, Glu175' and Tyr179' (the ' denotes that the residues are from the second monomer of the homodimer). Both these amino-acid residues and their structural arrangement are absolutely conserved between Mn-SOD<sub>Dr</sub> and Mn-SOD<sub>Ec</sub>.

Based upon the above comparison of the crystal structures of Mn-SOD<sub>Dr</sub> and Mn-SOD<sub>Ec</sub>, one can infer that their tertiary and quaternary structures are extremely similar and that the geometric and electrostatic properties of their catalytic centres are essentially identical. One might thus expect the activities of the two enzymes to be similar. However, in our hands (see §2.2), the measured activities of 1250 and 2740 U mg<sup>-1</sup> for Mn-SOD<sub>Dr</sub> and Mn-SOD<sub>Ec</sub> indicate that the activity of Mn-SOD<sub>Dr</sub> is rather lower than that of its *E. coli* counterpart. Thus, the importance of Mn-SOD to the radiation resistance of DEIRA cannot be attributed to a higher activity of Mn-SOD<sub>Dr</sub> with respect to that of Mn-SOD<sub>Ec</sub>.

It has been shown that in *E. coli* Mn-SOD preferentially protects DNA from damage caused by the presence of ROS (Hopkin *et al.*, 1992). This, coupled with later discovery that *E. coli* Mn-SOD binds in a non-specific manner to DNA (Steinman *et al.*, 1994), led to the suggestion that in *E. coli* Mn-SOD acts as a 'tethered antioxidant' which by binding to DNA concentrates its activity on scavenging superoxide radicals found close to DNA, thus preferentially ensuring its protection. The determination of the crystal structure of Mn-SOD<sub>Ec</sub> allowed the construction of a plausible model of how Mn-SODs and DNA might interact (see Figs. 6 and 7 of Edwards *et al.*, 1998). In this model, DNA binds in a positively charged semi-circular groove formed at the monomer–monomer interface of the Mn-SOD homodimer, with amino-acid side chains from two loops on the surface of each monomer (formed by residues 61–67 and 152–158, respectively) providing anchoring points for the DNA. Both the positive charge of the hemihedral groove and the amino acids in the DNA-anchoring loops are highly conserved between the structures of Mn-SOD<sub>Dr</sub> and Mn-SOD<sub>Ec</sub>. Therefore, it may well be that in DEIRA Mn-SOD plays the same role as it is proposed to play in *E. coli*.

As mentioned in §1, the only really significant difference between the amino-acid sequences of Mn-SOD<sub>Dr</sub> and Mn-SOD<sub>Ec</sub> is a six-residue insert of sequence QGQNGA between residues 91 and 92 (*E. coli* numbering; Fig. 1). In the crystal structures of Mn-SOD<sub>Dr</sub>, this region of the sequence forms part of a solvent-accessible loop joining the helices  $\alpha 1$  and  $\alpha 2$ . However, in the structures reported here and in that deposited in the PDB by Chan and coworkers, the residues making up the insert are disordered (Fig. 2) and are in a region of structure that is unlikely to affect either the active site or (potential) DNA binding by Mn-SOD<sub>Dr</sub>. However, they clearly point

away from the body of the Mn-SOD<sub>Dr</sub> structure. Thus, although there is currently no evidence to support such a hypothesis, it may be that the residues in this insert provide a means by which Mn-SOD<sub>Dr</sub> can interact with other proteins and thus act as a 'tethered antioxidant' protecting not only DNA but also proteins that are crucial to the radiation resistance of DEIRA.

The authors would like to thank the staff of Protein'xPert SA, Grenoble, France for carrying out initial cloning and expression tests on DR1279.

## References

- Battista, J. R. (1997). *Annu. Rev. Microbiol.* **51**, 203–224.
- Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* **D54**, 905–921.
- Borgstahl, G. E. O., Pokross, M., Chehab, R., Sekher, A. & Snell, E. H. (2000). *J. Mol. Biol.* **296**, 951–959.
- Chou, F. I. & Tan, S. T. (1990). *J. Bacteriol.* **171**, 2029–2035.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- DeLano, W. L. (2002). *The PyMOL Molecular Graphics System*. DeLano Scientific, San Carlos, CA, USA. <http://www.pymol.org>.
- Dojindo Molecular Technologies Inc. (2005). *SOD Assay Kit-WST Technical Manual*. <http://www.dojindo.com/newimages/SODKitTechnicalInformation.pdf>.
- Edwards, R. A., Baker, H. M., Whittaker, M. M., Whittaker, J. W., Jameson, G. B. & Baker, E. N. (1998). *J. Biol. Inorg. Chem.* **3**, 161–171.
- Edwards, R. A., Whittaker, M. M., Whittaker, J. W., Baker, E. N. & Jameson, G. B. (2001). *Biochemistry*, **40**, 4622–4632.
- Fridovitch, I. (1986). *Arch. Biochem. Biophys.* **247**, 1–11.
- Gouet, P., Robert, X. & Courcelle, E. (2003). *Nucleic Acids Res.* **31**, 3320–3323.
- Hopkin, K. A., Papazia, M. A. & Steinman, H. M. (1992). *J. Biol. Chem.* **267**, 24253–24258.
- Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. (1991). *Acta Cryst.* **A47**, 110–119.
- Levin-Zaidman, S., Englander, J., Shimoni, E., Sharma, A. K., Minton, K. W. & Minsky, A. (2003). *Science*, **299**, 254–256.
- Lipton, M. S. *et al.* (2002). *Proc. Natl Acad. Sci. USA*, **99**, 11049–11054.
- Makarova, K. S., Aravind, L., Wolf, Y. I., Tatusov, R. L., Minton, K. W., Koonin, E. V. & Daly, M. J. (2001). *Microbiol. Mol. Biol. Rev.* **65**, 44–79.
- Markillie, M. N., Varnum, S. M., Hradeky, P. & Wong, K.-K. (1999). *J. Bacteriol.* **181**, 666–669.
- Mattimore, V. & Battista, J. R. (1996). *J. Bacteriol.* **178**, 633–637.
- Minton, K. W. (1994). *Mol. Microbiol.* **13**, 9–15.
- Misra, H. P. & Fridovich, I. (1976). *Arch. Biochem. Biophys.* **176**, 577–581.
- Navaza, J. (1994). *Acta Cryst.* **A50**, 157–163.
- Parker, M. W. & Blake, C. C. F. (1988). *FEBS Lett.* **229**, 377–382.
- Steinman, H. M., Weinstein, L. & Brenowitz, M. J. (1994). *J. Biol. Chem.* **269**, 28629–28634.
- Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). *Nucleic Acids Res.* **22**, 4673–4680.
- Winn, M. D., Isupov, M. N. & Murshudov, G. N. (2001). *Acta Cryst.* **D57**, 122–133.